awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q37698921-4E4383E0-CA33-4D2E-9AD6-F44EFB2826C9
Q37698921-4E4383E0-CA33-4D2E-9AD6-F44EFB2826C9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37698921-4E4383E0-CA33-4D2E-9AD6-F44EFB2826C9
A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.
P2860
Q37698921-4E4383E0-CA33-4D2E-9AD6-F44EFB2826C9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37698921-4E4383E0-CA33-4D2E-9AD6-F44EFB2826C9
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4481dcc212d43ec7df87f7c95c40128bb080800e
P2860
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.